Introduction
In treating cancer of any organ the removal of that organ and the lymphatic nodes most commonly affected, together with the intervening lymphatics, is seemingly a most reasonable method of procedure. This hypothesis was responsible for the development of the classical operation of radical mastectomy, which during the first half of the twentieth century came to be regarded as the routine treatment in most cases of cancer of the breast confined, so far as could be judged, to the breast and the axillary lymph nodes of the same side. Since that time, however, certain theoretical aspects of the pathology of cancer in general have stimulated inquiry into whether this original concept always applies and whether, in removing the involved organ and the field of immediate lymphatic drainage, there may not be a debit as well as a credit side to the balance sheet. More and more evidence has accumulated to the effect that, quite early in the history of many cancers, malignant cells are liberated into the blood stream. It is likely that single malignant cells, or clumps of a few cells, are not generally capable of surviving. If they do often survive then, in those cases where they are found to be circulating, the wisdom of performing a formidable operation on the local condition must be questioned. If, on the other hand, they are destroyed, as we believe, then either they die a natural death or their survival is determined by an immune mechanism. This in itself prompts the consideration of whether more is gained by removing the cancer tissue than is lost by a major operation which might disturb both the humoral and the cellular immune processes designed to suppress them.
The work of Wallace Park and Lees (1951) , McKinnon (1954) , and Hardin Jones (1956) suggested that the results of treatment of localized cancer of the breast, as measured by survival rates, would be equally good with minimal surgical interference as with radical mastectomy. Mustakallio (1954) reported an 84% five-year survival rate in 127 patients with clinical stage 1 cancers who had been treated only by local excision and radiotherapy. Furthermore, the experience of surgeons such as Sir Arthur Porritt at St. Mary's Hospital, London, who practised a restricted form of surgery in selected cases, and of one of us (A.B.W.), to whom was sent, for radiotherapy only, cases where the local practitioner had removed a lump which had turned out to be a cancer, encouraged the belief that the outcome in these cases might compare not unfavourably with that of patients treated by orthodox radical mastectomy with or without radiotherapy. The report of Justin Fleming and Atkinson (1961) , analysing the results of 300 cases of carcinoma of the breast treated at St. Vincent's Hospital, Sydney, supported this view. At the Oncological Institute in Moscow restricted surgery with hormone therapy was freely practised in 1961.
In 1955 we considered the idea of testing the hypothesis that radical mastectomy was no more effective in preserving life in cases of early cancer of the breast than such restricted surgery as simple removal of the lump. We are indebted to Dr. W. J. Mann, who has proposed the term "tylectomy" from the Greek words "tyle" (Tur) or "tylos" (Taoas) a "lump" for excision of a lump and we use the term "extended tylectomy" instead of "wide excision" throughout the paper.
Before embarking on such a trial the evidence in favour of the BRITISH MEDICAL JOURNAL 20 MAY 1972 unorthodox method had to be so strong that all those engaged in the trial would be willing to allow their own relatives to enter it. As a result of the accumulation of the evidence quoted above, it seemed by 1961 not only ethical to conduct such a trial but imperative that this should be done in view of the mutilating character of one of the alternatives.
Present Trial
The trial as eventually designed was conducted as follows: the propositi were patients with carcinoma of the breast aged 50 or over who were judged suitable for radical mastectomy or extended tylectomy-namely, Manchester stages 1 or 2 (T, or , No or J). The two treatment programmes chosen by randomization were: (a) radical mastectomy and synoperative thiotepa in doses of 2 mg per stone (6A4 kg) body weight with premedication, 1-5 mg per stone on the second postoperative day, and 1 mg per stone on the fourth postoperative day, followed by radiotherapy; and (b) extended tylectomy, or wide excision, of the lump together with the surrounding breast tissue within 3 cm of palpable or visible growth and thiotepa administered as above, plus radiotherapy.
In 1961, when this investigation started, there were encouraging reports in the literature on the value of thiotepa as an adjuvant to mastectomy (Moore and Watne, 1961; Surgical Adjuvant Chemotherapy Breast Group, 1961) . The drug was therefore prescribed in small doses detailed above to all patients in the series. Subsequently the improvement in survival and recurrence following the use of thiotepa was reported to be minimal and to be confined to premenopausal patients with more than three lymph nodes involved (Noer, 1963; Cole et al., 1965) . As all the patients in this series were aged 50 or over, and hence mostly postmenopausal, it was decided not to persevere with this therapy, and no patient entering the trial after 1968 was given adjunctive chemotherapy. Those patients having an extended tylectomy were given the same course as the radical mastectomy patients exce t that the overall treatment time to the supraclavicular tri ingle and axilla was 12 days. In addition, the breast, including t'ie internal mammary chain, was treated with parallel opposing fields on a 6 MeV linear accelerator using "Lincolnshire belus" to bring the peak dose to the surface. A tumour dose of 3,500 3,800 rads in three weeks was given. This produced a reaction just bordering on moist desquamation.
Recurrence
In the event of recurrence each case was considered individually and the patient might receive further surgery, radiotherapy, hormone therapy, or endocrine ablatiot.
Cases were rejected if: (1) the lump was placed over the medial end of an intercostal space or rib (it was our practice to treat these patients, if clinically stage 1, by simple mastectomy and, if clinically stage 2, by radical mastectomy only if a biopsy of glands along the internal mammary artery showed that these were free from growth); (2) the referring doctor or the patient herself indicated that radical mastectomy was expected; (3) the patient presented with an involved gland in the axilla and no breast lump was palpable; (4) there was Paget's disease of the nipple; (5) the patient had received previous treatment for her breast cancer; or (6) there was a history of previous malignancy at another site.
The problem of informing the patient or her doctor that she was participating in a trial received careful consideration. One of us (H.J.B.A.), who was a member of the Medical Research Council's committee on the ethics of clinical trials, was able to establish to the satisfaction of that committee that, while in general terms it was preferable to inform a patient that he or she was included in a trial, when dealing with a potentially lethal condition for which the best treatment was not known, it would be improper to inform the patient that the choice of treatment was made randomly.
Follow-up Both groups were followed up at the breast clinic and were examined clinically at three-monthly intervals for the first three years, then at six-monthly-intervals for the next two years, then yearly. At these follow-up examinations routine skeletal surveys were not carried out and radiographs were taken only when the -patient complained of symptoms referable to a specific bone. The two groups were assessed at frequent intervals to determine whether any difference had emerged.
In an attempt to assess morbidity and quality of life after the two procedures each patient had to answer a questionnaire during the third and fifteenth months after operation. These questionnaires tested the patients' ability to cope with their normal duties and investigated their mental attitude to what had been done. The questionnaire had been designed by the late Dr. Henry Eisenberg, of the Connecticut Tumour Registry, and has been detailed elsewhere (Eisenberg and Goldenberg, 1968) . Also at these times the circumference of both arms was measured, 3 in (7-5 cm) below the acromion, 7 in (18 cm) above and 4 in (10 cm) below the olecranon, and at the wrist, to detect any postoperative lymphoedema. When the radiotherapy reaction had settled the size and shape of the original lump were drawn with a felt marker on the skin of the opposite breast of those patients who had had extended tylectomy. A colour photograph (distance 3 ft (90 cm)) was then taken of the patient with her arms behind her head to illustrate the size of her breasts relative to the lump and the deformity to the breast resulting from the operation.
Criteria of Assessment
It was decided that three criteria were to be used in the assessment of the results: the survival rate, the incidence and site of recurrence, and disability.
At first these three criteria were measured on the two populations, considering together those patients who were judged clinically to be free from deposits in the axilary lymph nodes 424 and those who were judged to have deposits in the axillary lymph nodes. As more material accumulated it was possible to consider these classes separately in the two populations.
We had a great deal of difficulty in deciding how to designate these two classes. The facts were that after analysing our findings in regard to the three criteria described above, we found that if the populations were divided into one group where the notes had indicated that in the opinion of the clinician the homolateral axillary nodes were free from invasion, and into another group where these nodes were considered to have been invaded, significantly different findings emerged in the two groups so distinguished.
Such a differentiation being a clinical one we are only too aware that it is in a scientific sense imprecise and depends on care, judgement, and experience. Nevertheless, that it has significance will appear when we describe our findings. After discussion within the unit and with outside experts, we decided to call the first group by the old-fashioned term "clinical stage 1" and the other "clinical stage 2" or, for brevity, "stage 1" and "stage 2." In the TNM system stage 1 is equivalent to N. and N,a and stage 2 to N,b.
It may well be that whether or not the lymph nodes harbour a few cancer cells is unimportant and that it is the size of the population of these cells within such nodes which is crucial and which, of course, is the most important factor in determining the clinical staging. The level of correspondence between clinical and pathological staging is shown in Table I . 
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This division into stages is the only stratification of our material which we have attempted. In a proportion of the patients the tumours have also been graded but an insufficient number has been investigated at present to warrant classification.
Criteria for Conclusion of the Trial This investigation was unlike most of such investigations since, in addition to a significant difference between the two treatments, a determinant result could be achieved-that is, the preferred method of treatment could be determined-if, after "adequate trial," there was no difference in survival rate, in which case the less formidable procedure would then be preferred.
When the trial was designed ten years ago we did not know what method of analysis of our results would prove to be the most sensitive and we set out as our criterion of determinance that either the survival rates or the distant recurrence rates (two of the three criteria of assessment described above) should be better by 10% after one method of treatment than after the other; this 10% betterment being demonstrable at an acceptable level of statistical probability. In the event, and by the methods of analysis which were applied, this somewhat rigid definition of determinance had to be modified, but the underlying principle was retained.
We decided that the investigation would be concluded
(1) when the 10% level in favour of one or other treatment had been achieved, or (2) when it could be shown that, at an acceptable probability level, a 10% betterment of one method of treatment over the other would never be achieved.
If a restricted operation were to challenge the efficacy of a more radical one, as in this investigation, the success of the former might well depend on an immune reaction to take care 425 of the small number of cancer cells, perhaps inevitably, left behind. We might be criticized therefore in that it was illogical to add cytotoxic drugs and radiotherapy (both of which agents might be supposed to damage the immune response) to the programmes of treatment in the two contrasted populations. We have no reply to this charge except to say that in 1961 when the trial began the evidence that cytotoxins and radiotherapy were damaging to the immune response was not sufficiently persuasive and we have so far modified our protocol only in respect of cytotoxins which are now no longer prescribed in either population.
Results
Throughout the ten years of the trial the death and recurrence rates of the two populations, taking stage 1 and stage 2 cases together, were monitored continuously by means of pegs on extensible threads, so that on any day it was possible to see at a glance the number of deaths and recurrences recorded in the two populations and any difference was readily appreciated. During all these years the pegs representing the survival of the two populations moved on almost in step so that at no time were we fearful that one method of treatment was curtailing the survival period of one population in respect of the other.
So far 370 patients have entered the trial. Of these, 188 have had a radical mastectomy and 182 an extended tylectomy. The average age of patients subjected to extended tylectomy was 61 0 years and to radical mastectomy 60-9 years. Other factors, such as average length of history and siting of the lumps within the breast, were sufficiently equally distributed between the two populations as to make them scientifically comparable (Table   II) . (Fig. 2) .
A statistical analysis of these results shows that in stage 2 cases radical mastectomy gives significantly better survival than that given by extended tylectomy at 10 years (0-025 < P < 0 05) but not at five years (0-3 < P < 0-4). However, the difference between radical mastectomy and extended tylectomy for the two groups of patients with stage 1 tumours in favour of extended tylectomy is not significant. Not only was the cosmetic result bad but also it was difficult to fit a prosthesis. On the other hand, when a small tumour was removed from a big breast there was minimal alteration in the size and shape of the breast, and a good cosmetic result was obtained in a patient in whom a mastectomy would have resulted in considerable mutilation. Table VII summarizes the main findings of an analysis carried out on the answers to the questionnaires set at 3 and 15 months after operation. It can be seen that three months after operation arm movements are more restricted in radical mastectomy patients than in those who had an extended tylectomy, but the difference disappears after 15 months. Also the patients' activity status and their attitude to what has been done are similar by 15 months after either operation. Only in the case of lymphoedema is there persistent higher incidence in radical mastectomy patients.
The only complication experienced by patients receiving extended tylectomy, but not those having a radical mastectomy, resulted from the course of irradiation to the breast. In a number of cases considerable fibrosis of the breast and sometimes "marbling" of the overlying skin resulted. Occasionally it was extremely difficult to distinguish between this fibrosis and (Atkins, 1968) , that if a trial was ethical to start with it is unethical to conclude it until an acceptable result has been achieved, the trial on stage 1 patients will continue. (1966, 1971) compared radical mastectomy with simple mastectomy in patients with clinically stage 2 breast cancer. Both groups of patients received postoperative radiotherapy. They were unable to show any appreciable difference in survival or recurrence up to ten years after operation. The difference between their results and ours is unlikely to be explained by the retention of the breast in the extended tylectomy patients. In our trial, if as primary treatment a simple mastectomy rather than an extended tylectomy had been carried out, there would probably have been little difference in the local recurrence rate. Recurrence in the breast was a rare development. Also the -radiotherapy regimen in their trial was almost identical with ours. Calculated as a tumour dose the simple mastectomy patients in Brinkley and Haybittle's trial were given 2,760 rads to the axilla compared with the 2,700 rads received by our patients. However, a large number of Brinkley and Haybittle's patients having simple mastectomy also had some dissection of the axilla, sufficient at least in 79% of the patients to comment on the histology of the nodes. Our current results suggest that if an excessive incidence of local recurrence and probably distant recurrence is to be avoided, clinically involved axillary nodes must be removed at the primary operation.
Our results suggest that there is no one treatment that should be applied exclusively to all cases of cancer of the breast at the stage of the disease when radical mastectomy is a practicable proposition. The importance of clinical staging would seem to be decisive and this would imply the exercise of clinical judgement and the value of experience. To what extent such judgement could be refined by the preliminary biopsy of a palpable axillary node remains to be determined (Lalanne, 1968; Forrest et al., 1970) ; but it has been shown that the presence of very small deposits in the lower axillary nodes, which is all that could be detected by such a biopsy, probably has little influence on the prognosis of the disease (Huvos et al., 1971 The work has in part been supported by a grant from the Cancer Research Campaign.
